Navigation Links
Labopharm Reports Results for First Quarter Fiscal 2008
Date:5/8/2008

- Once-Daily Tramadol Continues to Gain Market Share in Europe and Canada;

Company Preparing NDA for Trazodone Contramid(R) Once-a-Day -

LAVAL, QC, May 8 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its results for the first quarter ended March 31, 2008. All figures are in Canadian dollars unless otherwise stated.

"While we continue to make strong progress in the global commercialization of our once-daily tramadol product, we are preparing the New Drug Application for our second product, trazodone Contramid(R) once-a-day, for submission prior to year-end, and have initiated the Phase III clinical study for our third product, a twice-daily formulation of tramadol and acetaminophen," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "In our global commercialization program for once-daily tramadol, our product has been launched in 10 countries, including Poland earlier this year, and is steadily gaining market(1) share in Europe(2) and Canada. In February, the latest month for which data is available, our product was the best selling once-daily tramadol product in four of the five largest European markets."

Mr. Howard-Tripp added, "We are encouraged by the positive Phase III results for trazodone Contramid(R) once-a-day. One of the greatest challenges in treating depression is that up to 50% of patients discontinue their medication within six months of initiating treatment and, therefore would benefit from an alternative treatment option. Patients need rapid improvement of their depressive symptoms and may experience insomnia and agitation. Our study demonstrated that trazodone Contramid(R) once-a-day was statistically superior to placebo by the end of the first week of treatment and was associated with an improvement in overall sleep quality. Accordingly, we are optimistic about the prospects for our formulation in the market for antidepressants."

Financial Summ
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Mike ... sat down with Derek Fenwick, PT, MBA, GCS, ... that will stem from the passing of the ... (IMPACT Act). In this taping of the Infinicast, the ... XVIII of the Social Security Act to standardize post-acute ...
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
(Date:12/24/2014)... Steven Reinberg HealthDay Reporter ... guidelines from the American Diabetes Association (ADA) call for giving ... diabetes to help prevent heart disease. These new standards ... Cardiology and American Heart Association, which also recommend giving low- ... disease, including people with diabetes. "We agree that the ...
(Date:12/24/2014)... Texas (PRWEB) December 24, 2014 ... Industry is a professional and in-depth research report ... report introduces COC basic information, including its definition, ... analysis, news analysis, etc. This report also presents ... etc. Production is separated by regions, technology and ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3
... released new clinical guidelines for the treatment of exacerbations ... literature on current clinical practices. "This is the ... practices for pulmonary exacerbation of cystic fibrosis," said Susanna ... and director of the Cystic Fibrosis Center at Children,s ...
... N.C. Studies by researchers at Wake Forest University ... receptor in immature rats leads to profound, rapid brain ... mature. The N-methyl-D-aspartate (NMDA) receptor is activated ... released by brain cells. This allows calcium to enter ...
... at-risk American adults who would benefit from vaccination against seasonal ... believe they do not need them and are not inclined ... intend to take up the vaccine, nearly half get around ... Corporation* in Arlington, USA, and her team. Their work (1) ...
... prescriptions issued by GPs has been caused by a year ... drugs on a long-term basis, according to researchers from the ... printed edition of British Medical Journal ( BMJ ... number of new patients diagnosed with depression over 11 years, ...
... chance of success , THURSDAY, Oct. 22 (HealthDay News) -- ... offer the best chance of success with in vitro fertilization ... selecting embryos for implantation in the mother,s womb is highly ... IVF failure or multiple pregnancies," Dr. Emre Seli, an associate ...
... medication leads to better outcome, researchers say , ... say they have a better treatment for patients ... standard therapy. , Their study finds that treatment ... better short-term survival and with lower toxicity than ...
Cached Medicine News:Health News:New clinical guidelines for exacerbations in cystic fibrosis 2Health News:General anesthetics lead to learning disabilities in animal models 2Health News:General anesthetics lead to learning disabilities in animal models 3Health News:Flu shots not to be sneezed at 2Health News:Assessing Embryo Metabolism May Aid IVF Success 2Health News:Study Finds Less Toxic Treatment for Myeloma 2
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... MIVI-TRUST Phase III Program, Confirming... -- LEUVEN, Belgium, September 6, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... China, Sept. 3 /PRNewswire-Asia-FirstCall/ -- ... ... var ... by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
Cached Medicine Technology:ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 2ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 3ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 4ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 5ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 6ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 7ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 8ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 9ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's Potential to Transform the Treatment of Retinal Disorders 10China Sky One Medical Updates Financial Guidance for 2010 2China Sky One Medical Updates Financial Guidance for 2010 3China Sky One Medical Updates Financial Guidance for 2010 4China Sky One Medical Updates Financial Guidance for 2010 5China Sky One Medical Updates Financial Guidance for 2010 6China Sky One Medical Updates Financial Guidance for 2010 7China Sky One Medical Updates Financial Guidance for 2010 8
... chemiluminescence assay for the measurement ... serum. Growth Hormone (GH) is ... the anterior pituitary gland under ... hormone releasing hormone (GHRH) and ...
... the sulfate ester of DHEA, derived from ... DHEA in adrenal and extradrenal tissues. DHEA ... the adrenal cortex, and is a precursor ... relatively weak androgenic activity, which for unsulfated ...
... The DHEA-S ELISA kit is based ... separation. An unknown amount of DHEA-S present ... of DHEA-S conjugated with horse-radish peroxidase compete ... DHEA-S antiserum coated onto the wells. After ...
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM....
Medicine Products: